Regulatory & Legal

A tech firm is leveraging sound waves to overcome key hurdles in brain-computer interfaces, paving the way for advanced rehabilitation and assistive care.

The new IMAGE Pro Academy offers a full suite of business and marketing tools, aiming to redefine success for the industry's independent professionals.

LyfeSci's acquisition of Clinically Media aims to fix the clinical trial bottleneck by integrating patient recruitment, promising faster, more diverse studies.

Publishers embrace EdTech as Wiley's content meets Top Hat's AI, promising a future of personalized, data-driven education for millions of students.

PrizePicks uses self-aware humor with Marshawn Lynch and Adam Devine to critique industry gimmicks, focusing on its simple, fan-first fantasy sports app.

Following a $25M fundraise, former WA Health Secretary Dr. Shah joins Jaan Health, signaling a new era for AI-driven chronic disease management.

As cyber threats in healthcare escalate, CIVIE's HITRUST e1 certification signals a new standard for patient data protection in AI-driven medical tech.

The AI security firm regained reporting compliance, but a critical hearing and debt talks will decide its fate as it battles to stay on the exchange.

A new industry group aims to build trust in state-linked stablecoins by setting standards for disclosure and redemption, but is it self-regulation or a prelude to law?

Austrian firm AOP Health secures nationwide access for its rapid heart rate drug, Rapiblyk™, by partnering with top US distributors. What does this mean for critical care?

Unrivaled's renewed partnership with Mount Sinai isn't just a deal; it's a statement on player health, setting a new benchmark for women's pro sports.

Orrstown Financial Advisors is opening a dedicated 4,000 sq. ft. office, signaling a strategic push to enhance client service in a growing regional market.

Inogen reports modest growth and a pivotal return to positive EBITDA, yet a revenue miss from delayed B2B orders raises questions for its turnaround.

With a new board member and strategic investment, Kandu, Inc. is set to scale its brain-computer interface technology for stroke recovery.

A new study reveals payment failures cost billions as customer patience runs out in minutes, creating a crisis for retail and hospitality brands.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

Leasing begins at The Orchard, a new luxury giant in Long Island City. But as it sets records, it also raises questions about the neighborhood's future.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

Interim data suggests LX2020 is well-tolerated and may reduce dangerous arrhythmias by targeting the root cause of PKP2-associated cardiomyopathy.